Jae Hyun Bae
Overview
Explore the profile of Jae Hyun Bae including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
175
Citations
1814
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee S, Hong N, Kim G, Li J, Lin X, Seager S, et al.
Yonsei Med J
. 2025 Feb;
66(3):187-194.
PMID: 39999994
Purpose: Rare diseases occur in <50 per 100000 people and require lifelong management. However, essential epidemiological data on such diseases are lacking, and a consecutive monitoring system across time and...
2.
Bae J, Choi J, Kim N, Kim S
Mayo Clin Proc
. 2025 Jan;
100(2):235-248.
PMID: 39797863
Objective: To assess the comparative effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i), thiazolidinediones (TZD), and dipeptidyl peptidase-4 inhibitors (DPP-4i) for the cardiorenal outcomes and mortality in individuals with type 2...
3.
Jeon B, Chang H, Tae B, Park J, Yoon D, Bae J
Int Neurourol J
. 2025 Jan;
28(4):264-269.
PMID: 39765338
Purpose: We aimed to assess the clinical efficacy and safety of combining silodosin and solifenacin for overactive bladder (OAB) in females. Methods: A retrospective analysis of 586 females with OAB...
4.
Bae J, Cho Y
J Diabetes Investig
. 2024 Oct;
16(2):183-186.
PMID: 39460581
Several ongoing trials are evaluating incretin-based therapies, including GLP-1 receptor agonists, for their effects on CKD and MASLD. These studies will offer insights into their potential for metabolic diseases in...
5.
Lim S, Bae J, Oh H, Hwang I, Yoon Y, Cho G
Cardiovasc Diabetol
. 2024 Oct;
23(1):373.
PMID: 39438942
Background: The therapeutic effects of ertugliflozin, a sodium-glucose cotransporter 2 inhibitor, on cardiovascular outcome are not fully understood. This study aimed to evaluate the efficacy and safety of ertugliflozin on...
6.
Kim H, Kim H, Song J, Hong J, Lee E, Londhe A, et al.
Theranostics
. 2024 Oct;
14(16):6088-6108.
PMID: 39431021
Alzheimer's disease (AD) is a progressive neurodegenerative disease accompanied by neurotoxicity, excessive inflammation, and cognitive impairment. The peroxisome proliferator-activated receptor (PPAR) δ is a potential target for AD. However, its...
7.
Jeon B, Ko Y, Cha J, Kim C, Seo M, Lee S, et al.
J Korean Med Sci
. 2024 Oct;
39(38):e259.
PMID: 39376189
Background: While polystyrene microplastics (PS-MPs) are emerging as potentially significant health threats, linked to cancer and reproductive dysfunction, their precise effects on human health remain largely unknown. We aimed to...
8.
Won H, Bae J, Lim H, Kang M, Kim M, Lee S
J Lipid Atheroscler
. 2024 Oct;
13(3):215-231.
PMID: 39355405
Elevated blood cholesterol and triglyceride levels induced by secondary causes are frequently observed. The identification and appropriate handling of these causes are essential for secondary dyslipidemia treatment. Major secondary causes...
9.
Won H, Bae J, Lim H, Kang M, Kim M, Lee S
Korean J Intern Med
. 2024 Sep;
39(5):717-730.
PMID: 39252486
Elevated blood cholesterol and triglyceride levels induced by secondary causes are frequently observed. The identification and appropriate handling of these causes are essential for secondary dyslipidemia treatment. Major secondary causes...
10.
Bea S, Ko H, Bae J, Cho Y, Chang Y, Ryu S, et al.
Gut
. 2024 Sep;
74(2):284-294.
PMID: 39242193
Objective: To examine the hepatic effectiveness of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) through a head-to-head comparison with glucagon-like peptide-1 receptor agonists (GLP-1RA) or thiazolidinediones (TZD) in patients with metabolic dysfunction-associated steatotic...